drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous gene-modified T cells expressing a single CAR with two nanobody (VHH) antigen-binding domains targeting CD19 and CD22 to activate CAR signaling (CD3ΞΆ with costimulatory domains), leading to T-cell activation, expansion, cytokine release, and cytotoxic killing of B-lineage blasts.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are gene-modified to express a single tandem nanobody (VHH) CAR that binds CD19 and CD22 on malignant B cells; antigen engagement activates CD3z and costimulatory signaling, leading to T-cell activation, expansion, cytokine release, and perforin/granzyme-mediated cytotoxic killing, with dual targeting intended to reduce antigen escape.
drug_name
Nanobody-based CD19/CD22 tandem dual CAR-T cells
nct_id_drug_ref
NCT06880913